About two years ago (before Dr. Ken Culver was hired as ALK Positive Inc Director of Research and Clinical Affairs, and Colin Barton was still leading the ALK Positive Inc Medical Committee), Colin received an email from Dr. Justin Gainor and Dr. Jessica Lin from Massachusetts General Hospital, inviting ALK Positive Inc to contribute to a special series on “ALK-positive NSCLC” for the Translational Lung Cancer Research (TLCR) journal.
Translational Lung Cancer Research is an international, peer-reviewed, open-access journal, which was founded in March 2012 and is published monthly and distributed worldwide. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer and related thoracic disease.
Keep in mind, these articles were written with the intended audience being medical professionals, so some of it is rather technical.
However, we know many of you like to stay knowledgeable about this disease that has altered our lives, and stay tuned in to the latest research.
Here are all the articles, now published
- Current opportunities and challenges in ALK-positive lung cancer
- A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma
- Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer—a narrative review
- Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review
- Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review
- Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic lymphoma kinase
- Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review
- Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer—current status and future directions
- Patient-led advocacy in ALK-positive lung cancer
AUTHOR: Colin Barton
ALK Positive Inc Medical Committee member
